RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric Cancer

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Beijing Friendship Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorBeijing Friendship Hospital首都医科大学附属北京友谊医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07353684, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed gastric cancer or gastroesophageal junction cancer, predominantly adenocarcinoma.

    Inclusion criterion 2

  3. Use of systemic immunosuppressive therapy within 14 days prior to the first dose of study treatment.

    Exclusion criterion 7

  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

    Inclusion criterion 6

  5. Absolute neutrophil count ≥ 1.5 × 10⁹/L.

    Inclusion criterion 9

    Hemoglobin ≥ 90 g/L (9.0 g/dL).

    Inclusion criterion 10

    Platelet count ≥ 100 × 10⁹/L.

    Inclusion criterion 11

  6. Male participants must be surgically sterile or agree to use effective contraception during the study and for at least 12 weeks after the last dose

    Inclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07353684, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18-75 years at the time of enrollment, with an estimated life expectancy of ≥ 3 months.
  • Histologically or cytologically confirmed gastric cancer or gastroesophageal junction cancer, predominantly adenocarcinoma.
  • Unresectable locally advanced gastric or gastroesophageal junction adenocarcinoma (Stage III or IV), as determined by the investigator based on CT, MRI, and/or PET-CT.
  • Disease with conversion (translational) therapeutic potential, as assessed by the investigator.
  • No prior anti-tumor treatment, including chemotherapy, radiotherapy, targeted therapy, immunotherapy, or other systemic anticancer therapies.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • Adequate hematologic function within 14 days prior to enrollment:
  • White blood cell count ≥ 3.5 × 10⁹/L.
  • Absolute neutrophil count ≥ 1.5 × 10⁹/L.
  • Hemoglobin ≥ 90 g/L (9.0 g/dL).
  • Platelet count ≥ 100 × 10⁹/L.
  • Adequate hepatic function within 14 days prior to enrollment:Total bilirubin ≤ 1.5 × upper limit of normal (ULN);ALT and AST ≤ 2.5 × ULN in patients without liver metastases;ALT and AST ≤ 5 × ULN in patients with liver metastases;Adequate renal function:Serum creatinine ≤ 1.5 × ULN;Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment and agree to use effective contraception during the study and for at least 12 weeks after the last dose.
  • Male participants must be surgically sterile or agree to use effective contraception during the study and for at least 12 weeks after the last dose
  • Ability to understand and willingness to sign a written informed consent form
  • Expected to comply with study procedures and follow-up requirements

Exclusion Criteria:

  • HER2-positive gastric or gastroesophageal junction adenocarcinoma.
  • Conditions that may significantly affect oral drug absorption, including inability to swallow, persistent nausea or vomiting, chronic diarrhea, or intestinal obstruction.
  • Known hypersensitivity or allergy to adebrelimab, apatinib, oxaliplatin, S-1 (tegafur/gimeracil/oteracil), or any of their excipients.
  • History of severe allergic reactions to monoclonal antibodies.
  • Active autoimmune disease or autoimmune disorders requiring systemic treatment.
  • Congenital or acquired immunodeficiency.
  • Use of systemic immunosuppressive therapy within 14 days prior to the first dose of study treatment.
  • Administration of live attenuated vaccines within 4 weeks prior to the first dose or planned during the study period.
  • Severe infection within 4 weeks prior to initiation of study treatment.
  • History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
  • Evidence of interstitial lung disease, including pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-induced pneumonitis, or severely impaired pulmonary function.
  • Uncontrolled hypertension despite at least 3 months of antihypertensive treatment.
  • Uncontrolled clinically significant cardiovascular disease.
  • High risk of severe bleeding, as judged by the investigator.
  • Peripheral neuropathy of Grade > 2 according to CTCAE.
  • Participation in another interventional clinical trial within 4 weeks prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.
  • Any condition that, in the investigator's judgment, makes the participant unsuitable for study participation.

Quoted from ClinicalTrials.gov, NCT07353684, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07353684, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07353684